MARKET

LUMO

LUMO

Lumos Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.98
-0.03
-0.30%
Closed 16:00 09/20 EDT
OPEN
10.01
PREV CLOSE
10.01
HIGH
10.38
LOW
9.80
VOLUME
23.99K
TURNOVER
--
52 WEEK HIGH
36.72
52 WEEK LOW
7.23
MARKET CAP
83.41M
P/E (TTM)
-4.7225
1D
5D
1M
3M
1Y
5Y
Insider Buy: Lumos Pharma
MT Newswires · 09/10 17:18
Lumos Pharma to Participate in September Investor Conferences
AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global ...
GlobeNewswire · 09/02 12:00
BRIEF-Santé Health Ventures Reports 8.1% Stake In Lumos Pharma Inc As Of Aug. 20
reuters.com · 08/30 21:26
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
Simply Wall St. · 08/16 13:58
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 12:09
Lumos Pharma EPS misses by $0.01
Lumos Pharma (NASDAQ:LUMO): Q2 GAAP EPS of -$1.04 misses by $0.01. Revenue of $0.01M (-66.7% Y/Y) Press Release
Seekingalpha · 08/05 12:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LUMO. Analyze the recent business situations of Lumos Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LUMO stock price target is 27.00 with a high estimate of 35.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 107
Institutional Holdings: 5.47M
% Owned: 65.49%
Shares Outstanding: 8.36M
TypeInstitutionsShares
Increased
5
56.56K
New
5
230.15K
Decreased
12
386.92K
Sold Out
6
12.24K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Chief Executive Officer/Director
Richard Hawkins
President/Chief Operating Officer/Chief Scientific Officer
John McKew
Chief Financial Officer/Chief Accounting Officer
Lori Lawley
General Counsel
Bradley Powers
Other
David Karpf
Lead Director/Independent Director
Thomas Raffin
Independent Director
An van Es-Johansson
Independent Director
Chad Johnson
Independent Director
Kevin Lalande
Independent Director
Joseph McCracken
Independent Director
Lota Zoth
No Data
  • All
  • Financials
  • Insiders
More
About LUMO
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing and commercialization of products, and therapies for people with rare diseases. The Company's lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.

Webull offers kinds of Lumos Pharma Inc stock information, including NASDAQ:LUMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LUMO stock methods without spending real money on the virtual paper trading platform.